AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
The Trip Report
#6: Dr. Jeeshan Chowdhury – A Contrarian Approach to Psychedelic Drug Development
Sep 14, 2023
Dr. Jeeshan Chowdhury, Founder & CEO of Journey Colab, discusses their contrarian approach to psychedelic drug development, focusing on developing a synthetic form of mescaline. They also emphasize the importance of incorporating psychological and community support in addiction treatment. The podcast explores challenges within capitalist structures, significance of psychedelic research, duration of the psychedelic experience, integrating therapy into rehab centers, and plans for rolling out trials for safe delivery of psychedelic therapies.
44:34
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Journey Colab is developing a synthetic form of mescaline, embracing longer trips lasting 12 to 14 hours, challenging the trend of engineered shorter trips or non-hallucinogenic compounds.
- Journey Colab aims to integrate psychological and community support into clinical trials by partnering with rehab centers, emphasizing the importance of safe and high-quality psychedelic care while collaborating with established systems.
Deep dives
Psychedelics and the Square Peg Round Hole Problem
The podcast episode discusses the challenge of integrating psychedelics into existing infrastructure in psychiatry and mental health. The speaker emphasizes that psychedelics are not just pills, but complex substances that require additional components for effective treatment. The issue arises when trying to fit these complex substances into the existing round holes of traditional psychiatric treatments. The speaker mentions that some people have been cutting corners and trying to find ways to make psychedelics less psychoactive or shorter-lasting, but research suggests that these approaches may not be effective. The speaker expresses a preference for high-quality care that incorporates intensive psychotherapy, and highlights the opportunity to integrate psychedelics into existing rehab centers that already offer evidence-based care. The speaker acknowledges the challenges and stigma surrounding medication-assisted treatments in rehab settings, but believes that a new model integrating psychedelics into rehab can provide safe and effective care at scale.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode